Company news
Verrica Pharmaceuticals Inc. news in 2024
Verrica Pharmaceuticals Inc.'s news releases, calls and decks from 2024, newest first.
Verrica Provides Business and Operational Update
December 19, 2024
Verrica Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
December 8, 2024
Verrica Pharmaceuticals Announces that Development Partner Torii Pharmaceutical Files New Drug Application of TO-208 the Treatment of Molluscum Contagiosum in Japan
December 5, 2024
Verrica Announces Pricing of $42.0 Million Public Offering
November 20, 2024
Verrica Announces Proposed Public Offering
November 19, 2024
Verrica Pharmaceuticals Reports Third Quarter 2024 Financial Results and Announces Leadership Transition
November 3, 2024
Verrica Pharmaceuticals Announces Acceptance of Two Abstracts Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2024 Fall Clinical Dermatology Conference
October 23, 2024
Verrica Pharmaceuticals Announces Restructuring of Commercial Organization
October 1, 2024
Verrica Pharmaceuticals Reports Second Quarter 2024 Financial Results
August 13, 2024
Verrica Pharmaceuticals Announces Positive Preliminary Topline Results from Part 2 of Phase 2 Clinical Study of VP-315, an Investigational Oncolytic Peptide-Based Immunotherapy for the Treatment of Patients with Basal Cell Carcinoma
August 13, 2024
Verrica Pharmaceuticals Announces Litigation Settlement with Dormer Laboratories, Inc.
June 30, 2024
Verrica Pharmaceuticals Announces Amendment to Company’s Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts
May 14, 2024
Verrica Pharmaceuticals Reports First Quarter 2024 Financial Results
May 12, 2024
Verrica Pharmaceuticals Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference
April 1, 2024
Verrica Pharmaceuticals Announces that YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from the FDA
March 25, 2024
Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results
February 28, 2024
Verrica Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full-Year 2023 Financial Results on February 29, 2024
February 21, 2024
Verrica Pharmaceuticals Receives Permanent J-Code (J7354) for YCANTH™ from Centers for Medicare and Medicaid Services
January 28, 2024
Verrica Pharmaceuticals Announces Last Patient Dosed in Part 2 of Phase 2 Study of VP-315, a Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell Carcinoma
January 4, 2024
Verrica Pharmaceuticals Announces Receipt of Minutes from Type C Meeting with FDA Regarding Clinical Development of YCANTH™ for the Treatment of Common Warts
January 3, 2024
Verrica Pharmaceuticals Announces Specialty Pharmacy Partnership Agreement with Walgreens to Distribute YCANTH™
January 2, 2024
Calls in 2024
Decks in 2024
- Investor Presentation (August 2024)
Investor deck · 59 slides · August 2024
- Investor Presentation (May 2024)
Investor deck · 48 slides · May 2024
- Investor Presentation (January 2024)
Investor deck · 51 slides · January 2024